



Workshop 3

The Shifting Landscape of AYA Cancer Treatment: A collaborative workshop exploring international best-practice, advances and challenges in the treatment of AYA malignancies

Date	Monday 3 December 2018
Time	11am – 5pm
Venue/Room	Karstens - 111 Harrington Street, Sydney: 1.14 Medium Room
Cost	\$220 AUD early bird, \$290 AUD standard registration (<i>limited capacity</i>)

WHO IS THIS FOR

This workshop will include content relevant to those involved in the medical treatment of adolescents and young adults with cancer or with an interest in the ongoing advances and opportunities in this field. This may include haematology / oncology physicians, clinical trialists, nurses, health service and program managers, policy makers or researchers across the translational pathway.

PRESENTERS

- ❖ Prof Stuart Seigel – *Professor of Paediatrics and Medicine, Keck School of Medicine, University of Southern California, USA*
- ❖ Dr Mandy Ballinger – *Group Leader - Genetic Cancer Risk, The Garvan Institute of Medical Research, AUSTRALIA*
- ❖ Prof Winette van der Graaf – *Professor of Personalised Oncology, The Royal Marsden, UK*
- ❖ Dr Rebecca Johnson – *Medical Oncologist, Division of Paediatric Haematology/Oncology, Mary Bridge Hospital, USA*
- ❖ A/Prof David Ziegler – *Senior Staff Specialist & Head, Clinical Trials Program, Kids Cancer Centre, Sydney Children's Hospital, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, AUSTRALIA*
- ❖ Dr Craig Nichols - *Director of the Precision Genomics Cancer Research Clinic, Intermountain Healthcare, USA*
- ❖ A/Professor Mustafa Khasraw - *Principal Research Fellow and Clinical Lead, NHMRC Clinical Trials Centre, Sydney Medical School and Medical Oncologist at Royal North Shore Hospital in Sydney*
- ❖ Dr Ken Micklethwaite - *Clinical Haematologist and Blood & Marrow Stem Cell Transplant staff specialist at Westmead Hospital in New South Wales*

WORKSHOP OVERVIEW

Split into three sessions over the course of the day, with a networking lunch provided, in this workshop we will hear updates and insights into:

- Acute Lymphoblastic Leukaemia in AYAs
- New Developments in CAR-T therapies
- Familial cancer in AYAs
- Sarcoma in AYAs
- Breast Cancer in AYAs
- Germ Cell Tumours in AYAs
- Medulloblastoma in AYAs
- Glioblastoma in AYAs

The day will conclude with a panel discussion exploring the question of “What are the international biomedical research priorities in AYA cancer?”

CONVENORS



Dr Michael Osborn

Dr Michael Osborn has been the lead clinician of the Youth Cancer Service SA/NT at the Royal Adelaide Hospital since its inception in 2011. He is dual-trained in both adult haematology and paediatric haematology / oncology, and is also a consultant paediatric haematologist / oncologist at the Women's and Children's Hospital in South Australia. Michael was actively involved in the development and implementation of Youth Cancer Services in Australia at a national and state level.

His main clinical and research interests are leukaemia in children and AYA, exercise in cancer, and improving healthcare delivery for children and AYA with cancer. He is a co-investigator for a number of projects currently being undertaken by the Leukaemia Research Group at the South Australian Health and Medical Research Institute (SAHMRI), as well as being the local principal investigator for several co-operative group and pharmaceutical company sponsored clinical trials.



Professor Stuart Siegel

Stuart Siegel is a retired Professor of Pediatrics and Medicine at the Keck School of Medicine of University of Southern California as well as the former Director of the Center for Global Health at Children's Hospital Los Angeles. He was the Founding Director of the Children's Center for Cancer and Blood Diseases and the Center for International Health at Children's Hospital Los Angeles, Co-Founding Medical Director of the USC/Norris AYA Oncology Program, and the first holder of the

Stuart E. Siegel, M.D. Endowed Chair in Pediatric Oncology at Keck School of Medicine of USC. He has also held leadership roles in the National Leukemia Broadcast Council, the Make-a-Wish Foundation, and the American Cancer Society and was on the Board of CHLA. He is currently the President of the boards of CureSearch and the Health Care Foundation for Ventura County and is on the boards of the Chase Foundation, Ronald McDonald House Charities Global and the Southern California Ronald McDonald organization. Dr. Siegel's involvement in the area of Adolescent and Young Adult (AYA) Oncology began with his participation in the joint Lance Armstrong Foundation - NIH sponsored Progress Review Group in 2003. He then served in leadership positions on the Organizing Committee of the Lance Armstrong Foundation's Young Adult Cancer Alliance, and currently is the Chair of the board of the successor organization, Critical Mass. He developed and implemented one of the first academic programs in AYA Oncology in the USA as well as the first US medical student and post-specialty clinical and research training programs in AYA oncology. He is the second recipient of the Archie Bleyer, M.D. Trailblazer Award from Critical Mass in 2015 and was an Associate Editor of the first edition of the first AYA oncology textbook, "Cancer in Adolescents and Young Adults."



Dr Mandy Ballinger

Dr Mandy Ballinger is a Group Leader at the Garvan Institute of Medical Research and holds a Fellowship from the Cancer Institute NSW. Mandy oversees a program of work focused on defining heritable cancer risk and using research cohorts as vehicles for intervention to impact on clinical practice and improve outcomes for families.

Professor Winette van der Graaf

Professor van der Graaf was trained and worked as a medical oncologist in university medical centres in Groningen and Nijmegen in the Netherlands. Before she joined the Sarcoma team at The Royal Marsden and was appointed as Professor of Personalised Oncology at the Institute of Cancer Research (ICR) in 2015 she headed the Department of Medical Oncology at the Radboud University Medical Centre. She was chair of the EORTC Soft Tissue and Bone Sarcoma Groups from 2011-2014, and remains a board member. Her main interests are in translational research in sarcoma, where observations in clinical practice can be brought back to the lab and vice versa, and on clinical trials including novel diagnostic approaches and agents. She is passionate about finding better treatments for patients with bone and soft tissue sarcomas and about research focused on improvement of sarcoma patients' quality of life.

Dr Rebecca Johnson

Dr Rebecca Johnson is the Medical Director of the Adolescent and Young Adult (AYA) oncology program at Mary Bridge Children's Hospital (MBCH) in Tacoma, WA. Prior to joining MBCH she founded the Adolescent and Young Adult (AYA) oncology program at Seattle Children's Hospital and served as its Medical Director.

Dr Johnson provides consultation and care to paediatric oncology and haematology patients, including children with haemophilia and sickle cell disease. She trained at Jefferson Medical College, Philadelphia, completing her residency at Milton S. Hershey Medical Center / Pennsylvania State University in Paediatrics and Internal Medicine and fellowship at Baylor College of Medicine in Paediatric Haematology and Oncology, Molecular and Human Genetics and Paediatric Oncology Clinical Research.



A/Professor David Ziegler

A/Prof David Ziegler is a paediatric oncologist at Sydney Children's Hospital and Group Leader at the Children's Cancer Institute. From 2005-2007 he was a Fulbright Scholar at Harvard Medical School. Currently, he is head of the Clinical Trials Program at the Kids Cancer Centre at Sydney Children's Hospital where his clinical research focuses on early phase clinical trials. He also leads the Targeted Therapy laboratory group at the Children's Cancer Institute Australia. This group is investigating novel therapies for childhood brain tumours, including

medulloblastoma, diffuse midline glioma, and other malignant gliomas. David has established a national tumor bank for these brain tumours, and a program using robotic high-throughput screening technology to discover new treatment strategies for diffuse midline glioma. He leads the national childhood cancer personalized medicine trial in Australia, which involves all Australian childhood cancer centres. He was recently awarded a grant to run a national clinical trial for Australian AYA with medulloblastoma.

Dr Craig Nichols

Dr. Craig Nichols directs the Precision Genomics Cancer Research Clinic Intermountain Healthcare. He previously worked at the Virginia Mason Medical Center in Seattle where he led the multi-disciplinary testicular cancer program and was the principal investigator for the Northwest National Cancer Institute Community Oncology Research Program.

Over the last decade, Dr. Nichols has served on the board of LIVESTRONG and the Oregon chapter of the Leukemia/Lymphoma Society. He also runs a nonprofit dedicated to information and knowledge exchange in testicular cancer. Dr. Nichols continues to serve as the executive officer for one of the nation's largest cancer research groups — SWOG — for community based cancer research, adolescent and young adult oncology, survivorship, patient advocacy and digital engagement. He was recently elected to the board of the American Society of Clinical Oncology and serves on its executive committee.

Dr. Nichols' clinical work and research has largely focused on AYA oncology, lymphoma and testicular cancer. More recently he has focused on precision medicine with early phase agents and his research has addressed cancer care delivery, big data and comparative effectiveness research.



A/Professor Mustafa Khasraw

Associate professor Mustafa Khasraw, MBChB MD FRCP FRACP, is Principal Research Fellow & Clinical Lead at the National Health Medical Research Council Clinical Trial Centre at The University Of Sydney. He is a medical oncologist at Royal North Shore Hospital (RNSH) and The Northern Cancer Institute at St Leonards, Sydney and cancer research fellow at Deakin university with a leading role in several clinical and translational programs.

Associate professor Khasraw is principal investigator on phase I, II and III clinical trials in solid tumours. He is the chief investigator on NHMRC funded research into the treatment and biomarker discovery for glioblastoma (GBM), neuroendocrine (NET) and a number of other cancer types.

He is the author of numerous peer-reviewed publications in clinical and translational research in cancer and has presented his work at international conferences and meetings on more than 50 occasions.

Reflective of his research standing, he sits on several research and grant review committees.



Dr Ken Micklethwaite

Dr Ken Micklethwaite is a Clinical Haematologist and a Blood and Marrow Stem Cell Transplant staff specialist at Westmead Hospital in New South Wales, with a particular focus on leukaemia and lymphoma. He is also Medical Director of the Sydney Cellular Therapies Laboratory here in Australia. He did a PhD in cellular therapy of CMV in the setting of allogeneic stem cell transplant at Westmead Hospital and post-doctoral research in combining gene and cell therapy of infection and malignancy at the Center for Cell and Gene Therapy, in Houston

Texas. His primary research interest is incorporating cell and gene therapy into the routine treatment of malignant haematological conditions. He is currently principal investigator on two chimeric antigen receptor T-cell trials targeting B-cell malignancies and co-investigator on multiple infection-specific cellular therapy trials. He is Chair of the Australian Therapeutic Goods Administration Advisory Committee on Biologicals and Co-Chair of the International Society for Cell and Gene Therapy Immuno-Gene Therapy Committee.